G-protein-coupled receptors serve as key signal transduction conduits, linking extracellular inputs with diverse cellular responses. These receptors eluded structural characterization for decades following their identification. A landmark structure of rhodopsin provided a basis for structurefunction studies and homology modeling, but advances in receptor biology suffered from a lack of receptor-specific structural insights. The recent explosion in GPCR structures confirms some features predicted by rhodopsin-based models, and more importantly, it reveals unexpected ligand-binding modes and critical aspects of the receptor activation process. The new structures also promise to foster studies testing emerging models for GPCR function such as receptor dimerization and ligand-biased signaling.
Introduction G-protein-coupled receptors are seven transmembrane domain (TM) proteins that are located in the plasma membrane and transduce signals through their interactions with both extracellular small-molecule ligands and intracellular G proteins to initiate signaling cascades that allow cells to respond to changes within their environment. With more than 800 members in the human genome, G-protein-coupled receptors (GPCRs) represent the largest family of proteins involved in signal transduction across biological membranes. They recognize a large diversity of hormones and neurotransmitters and, as a consequence, are major targets for the development of drugs for many clinical indications. They have been grouped in five or six classes (depending on the classification criteria used), with most of them belonging to classes A (rhodopsin-like), B (secretin-like), and C (metabotropic glutamate-like) that are defined by the conservation of unique structural features (Foord et al., 2005) . GPCRs generally operate within a transduction unit containing the receptor that binds the soluble signal, a heterotrimeric (abg) G protein, and an effector component such as an enzyme or a channel that promotes the intracellular changes leading to a biological response (Figure 1 ). Ligand binding activates GPCRs, which then mediate a nucleotide exchange reaction for the associated Ga subunit. In general, drugs binding at GPCRs were believed to act exclusively by promoting this reaction. More recently, the ability of GPCRs to signal in a G-protein-independent manner through their direct interactions with other effectors such as b-arrestin has also emerged (Galandrin et al., 2007) .
In the last three decades, numerous cellular, biochemical, and biophysical studies have provided a general appreciation of how GPCRs function. However, these studies do not offer a detailed description of the molecular events linking ligand binding to receptor activation. Major efforts to obtain high-resolution GPCR structures were therefore driven by the idea that threedimensional crystal structures would provide an atomic narrative of the conformational changes leading to the activation of G-protein-dependent and -independent signaling, thus yielding the needed information to understand drug action and support rational design.
Although GPCRs have been known for more than 40 years, the first high-resolution structure, that of the visual receptor rhodopsin, wasn't solved until 2000 (Palczewski et al., 2000) , and another 7 years were needed for the determination of the first GPCRs bound to diffusible ligands such as hormones or neurotransmitters Rasmussen et al., 2007; Rosenbaum et al., 2007) . The delay in generating crystal structures of GPCRs other than rhodopsin resulted largely from methodological difficulties associated with the crystallization of transmembrane proteins. Recent technological advances in engineering, producing and purifying membrane proteins, crystal formation, and X-ray diffraction paved the way for the recent explosion of GPCR structural biology work. In the last 5 years, 47 structures representing 13 distinct GPCRs have been solved-in many cases with resolution of 3 Ǻ or better (Table 1) .
Early Days of Structure and Modeling
Using electron microscopy, Henderson and Unwin (1975) generated the first three-dimensional structure of a 7TM protein from diffraction images of Halobacterium halobium bacteriorhodopsin, a highly expressed proton pump. Once the cloning of GPCRs revealed their 7TM topology, the bacteriorhodopsin structure, as well as the subsequently solved 3D projection maps of eukaryotic rhodopsin (Schertler et al., 1993) , became templates of choice to model GPCRs (Baldwin et al., 1997; Henderson et al., 1990) . Although these models were quite useful in driving early site-directed mutagenesis studies and for probing the structure-activity relationship of the receptors, the relatively low resolution (>9Ǻ) prevented detailed analyses. An important step forward toward a more precise representation of GPCRs came with the high-resolution (2.8 Ǻ) structure of the bovine dark-adapted rhodopsin (Palczewski et al., 2000) , which allowed an accurate determination of amino acid side chain conformations, as well as the extracellular and intracellular loops and the N-and C-terminal domains.
Collectively, the information gained from these models provided structural explanations for the role of specific sequence features that are highly conserved among the large class A subgroup of GPCRs that include rhodopsin, the monoamine receptors, and numerous peptide and lipid receptors. (This review will focus on class A receptors for which the principal structural advances have been realized.) It was previously shown for these receptors that a sequence element, termed the DRY (or E/DRY) motif, played a role in controlling receptor activity. The structural models revealed the presence of a polar interaction between an arginine located at the bottom of TMIII and a glutamate on TMVI, providing a structural explanation for the role of this conserved features. The so-called ''ionic lock'' formed between TMIII and TMVI was proposed to stabilize the inactive state of the receptor (Figures 1 and 2 ). Consistent with this notion, biophysical studies on rhodopsin (Altenbach et al., 2008 ) and the b 2 -adrenergic receptor (b 2 AR) (Yao et al., 2006) showed that disruption of the interaction leads to TMVI movement away from the TM bundle, creating a crevice to cradle the heterotrimeric G protein. The similar findings for rhodopsin and the b 2 AR popularized the notion that ligand binding would lead to full receptor activation through a common conserved mechanism. Yet, the lack of a 3D structure for an activated receptor prevented a complete understanding of the molecular processes linking ligand binding to receptor activation.
Methodological Breakthroughs
Seven years following the crystallization of mammalian rhodopsin, the structure of human b 2 AR in complex with the b-adrenergic antagonist carazolol was solved Rasmussen et al., 2007; Rosenbaum et al., 2007) . Attaining this goal required major methodological hurdles to be overcome. First, large quantities of homogeneous receptor were neededa task that was complicated by the lower expression of GPCRs binding diffusible ligands compared to rhodopsin. This problem was circumvented by overexpressing the receptors in specialized systems while the sources of microheterogeneity such as putative phosphorylation and glycosylation sites were eliminated by mutagenesis. Second, the stability of these intrinsically dynamic GPCRs needed to be increased to avoid aggregation and to facilitate crystal lattice packing. Because the third intracellular loop (ICL3) ( Figure 1 ) is a particularly flexible domain, different strategies were designed to stabilize this part of the receptor. In a few cases Bokoch et al., 2010) , an antibody Fab fragment recognizing ICL3 was bound to the receptor. In many other cases, ICL3 was deleted and replaced by well-folded soluble proteins such as T4 lysozyme Jaakola et al., 2008; Rosenbaum et al., 2007; Wu et al., 2010 Wu et al., , 2012 or the apocytochrome b564RIL . Thermo-stabilizing mutations have also been used to obtain receptor preparations compatible with crystal formation (Warne et al., 2008; Doré et al., 2011; Lebon et al., 2011) . The residues selected to stabilize the receptors were first identified empirically by testing a very large number of mutations and selecting those with the greatest impact on stability. In most cases, between four and eight mutations were needed to obtain the required stability. As for many membrane proteins, GPCR crystallization requires conditions adapted to the hydrophobic nature of the protein. In an effort to satisfy this requirement, several methods, including detergent-based micelles, bicelles (Faham and Bowie, 2002) , and in particular, lipidic cubic phase systems (Landau and Rosenbusch, 1996; Pebay-Peyroula et al., 1997) , were developed and used successfully. Despite optimized conditions, GPCR crystals tend to be small. The development of microfocus X-ray synchrotron technologies that deliver a microscale beam to a crystal (Riekel et al., 2005) greatly contributed to generating the high-resolution structures.
An Explosion of Structures
The wealth of structural information emerging over the last 5 years (Table 1) forms the basis of a real revolution in GPCR research. The structural and functional models that arise from them have changed our views on GPCR agonist and antagonist binding modes and on the activation processes.
Ligand Recognition
As expected, the overall folding of the TM domain is highly conserved among all structures and was well predicted by the . TM domains are shown as ribbons, whereas the important residues of the E/DRY, ionic lock, and NPXXY motifs are shown as stick renderings and are indicated by solid lines. The structure of rhodopsin represents the inactive conformation of the receptor, whereas the opsin structure is in an active-like conformation. The dotted circles overlaid on the opsin structure indicate the positions of TMV, TMVI, and TMVII in the inactive rhodopsin, and the orange dotted arrows illustrate the TM movements from inactive to active states. The ionic interaction (ionic lock), represented by a dotted line between the R of the E/DRY motif and a negatively charged glutamate (E) residue in TMVI, is believed to stabilize the receptor in an inactive state. In the opsin structure, an active-like retinal-free state of rhodopsin, the disruption of the ionic lock allows TMVI to move away from the receptor bundle and down toward the cytoplasmic interface with the heterotrimeric G protein. Simultaneously, the tyrosine (Y) residue of the NPXXY motif moves inside the bundle, blocking TMVI in an open conformation. The ionic lock is, however, not found in most of the antagonist-bound GPCR structures obtained to date. This is exemplified here by the structure of the b2AR bound to the antagonist (inverse agonist) carazolol, where the ionic lock is not formed, indicating that an alternative configuration is involved in the stabilization of the closed state of the receptor. structures of eukaryotic rhodopsin, showing only modest differences in the relative orientation of the TMs. However, more striking differences are found in the extracellular loop domains and especially in the second extracellular loop (ECL2) that clearly displays receptor-specific folds (Figure 3 ). These domains act as a vestibule directing the way ligands access the receptorbinding pocket. For example, the ECL2 of many receptors, including the b 2 AR (Figure 3 , top left), form a compact helical shape adjacent to the TM bundle that, along with the small ECL1 and ECL3, allows soluble ligands to diffuse easily from the extracellular compartment toward the binding site inside of the receptor bundle . In contrast, as was observed for rhodopsin (albeit through a different fold), the ECL2 of the S1P 1 receptor, along with ECL1 and the N-terminal helices, seals off the ligand-binding pocket (Figure 3 , top right), blocking access from the extracellular milieu (Hanson et al., 2012) . The structure suggests that the lipid agonist S1P accesses the receptor by a TMI-TMVII intrabundle opening near the plasma membrane. Interestingly, the extent of opening of each receptor's ''mouth'' determined by the relative position of ECL2 varies considerably between receptors, revealing an unexpected diversity of ligand entry mechanisms. In addition to their role in channeling the ligands toward the binding pocket, these extracellular domains have been suggested to contribute to both binding kinetics and selectivity (Dror et al., 2011) .
As the structures have revealed diversity in how ligands access the receptor, so too have they illuminated specific aspects of ligand recognition. Classical views of how ligands might bind were sculpted by generalization from the retinal/ rhodopsin structure (Palczewski et al., 2000) and early aminergic receptor modeling (Flower, 1999) , in which ligands were predicted to lie parallel to the plane of the membrane deep in the TM bundle (Figure 3, top left) . The new structures broaden our understanding on this front. For instance, both agonists and antagonists (Figure 3 , bottom left) of A 2A adenosine receptor (A 2A AR) bind in an extended conformation perpendicular to the plane of the membrane where they are stabilized by extensive contacts with ECL2 and ECL3 (Doré et al., 2011; Jaakola et al., 2008; Xu et al., 2011) . For CXCR4 (Figure 3, bottom right) , the antagonist IT1t unexpectedly binds the receptor at its surface between TMVII, TMI, TMII, and ECL2 (Wu et al., 2010) . In contrast, b 2 AR shows the ''canonical'' deep TMVI-TMIII-TMV aminergic binding pocket (Figure 3, top left) , as do the muscarinic M2 and M3 receptors (M2R and M3R), although ligands for these latter receptors are protected by a three-dimensional aromatic cage (Haga et al., 2012; Kruse et al., 2012) . Similarly, the S1P 1 R antagonist ML056 (Figure 3 , top right) binds a highly hydrophobic and polyaromatic region deep in the receptor, but the ligand also projects phosphate and amine groups vertically toward charged and polar residues packed between the N-termini, ECL2, TMVII, TMII, and TMIII (Hanson et al., 2012) . It should also be noted that the size of the binding sites greatly diverges among receptors, ranging from the small compact binding pocket of the eticlopride-bound dopamine receptor to the large surface of the CXCR4-binding pocket required to accommodate the fold of the bound CVX15 peptide (Wu et al., 2010) . These results clearly indicate that each receptor has a binding site that is specifically adapted to the nature of its ligands. These data open new perspective in the rational design of ligands that are better adapted to unique binding pockets.
The rich diversity of the ligand-receptor complexes indicates that ligand selectivity cannot be simply explained by different amino acids within shared ligand binding pockets, but that it also depends on the overall receptor architecture involving residues in different domains of the receptor. A good example is provided by the b 1 AR and b 2 AR structures that revealed a very high degree of identity between the residues found in the ''canonical'' aminergic binding pocket (Warne et al., 2008) despite the existence of clear receptor subtype selectivity. Such selectivity has been proposed to result in part from ligandinduced conformational changes (Wacker et al., 2010) and to involve interactions with ECL residues (Audet and Bouvier, 2008; Rosenbaum et al., 2007; Warne et al., 2008) . A role for residues close to the extracellular domains in determining the ligand binding selectivity was also observed for the recently solved structure of the delta-opioid receptor . The crystal structure of the nociceptive/orphanin FQ receptor (NOP) also shows that most of the residues that are different between NOP and the other members of the opioid receptor family are not in direct contact with the ligand in the binding pocket but rather are involved in large pocket reshaping and water coordination.
The diversity in binding modes also has important implications for the activation process of the receptors, as it suggests that no unique activation trigger can be invoked for all GPCRs. Instead, the engagement of distinct regions of the receptors by their ligands predicts that different allosteric transitions will be needed to reach a common active state. Activation and Allosteric Transition GPCR ligands can be divided into two general classes: agonists that promote and antagonists that block receptor activation. Antagonists can be subdivided into inverse agonists, which inhibit the spontaneous (agonist-independent) activity of the receptors, and neutral antagonists that are devoid of intrinsic activity and block the action of both agonists and inverse agonists. Out of the 47 ligand-bound GPCR structures, 36 were cocrystallized with antagonists (including 16 with inverse agonists), whereas 11 were cocrystalized with agonists (Table  1) . Somewhat surprisingly, few differences could be seen between the agonist and antagonist-bound forms, yielding relatively little information on the dynamics of receptor activation and on the conformational changes underlying ligand-promoted activation. Exemplifying this point is the observation that structures of the G-protein-free b 2 AR cocrystalized with full or partial agonists are very similar to those with antagonist or inverse agonist and mostly display the characteristics of an inactive conformation (Figure 4) . These limited changes are consistent with a model for full GPCR activation that requires both ligand binding and G protein engagement.
Fortunately, three structures provided significant insights in the activation mechanism. The first one is a ligand-free form of opsin that is cocrystalized with the C terminus of the a-subunit of the heterotrimeric visual G protein, transducin (Scheerer et al., 2008) . This structure confirmed earlier predictions about TMVI movement from site-directed mutagenesis and biophysical studies. When compared with dark-adapted rhodopsin, a large outward movement of TMVI and disruption of the ionic lock between TMIII and TMVI were observed (Figure 2 ). In addition, this structure provided new insight into conformational rearrangements that facilitate G protein binding. In the active opsin, TMVII bends inward, allowing the repositioning of the tyrosine from the conserved NPXXY motif, which prevents the reverse movement of TMVI, thus stabilizing the open state that forms a cradle for transducin (Figure 2 ). In parallel, the arginine of the DRY motif juts into the bundle of the receptor, providing an interacting floor for transducin's C terminus. TMV is also repacked against TMVI, offering an additional interacting surface for the G protein.
The two additional structures that provided insights into the activation process are the agonist-bound b 2 AR stabilized in the active conformation by a nanobody mimicking the G protein (Rasmussen et al., 2011a ) and the agonist-bound b 2 AR cocrystallized with heterotrimeric stimulatory G protein (Gasb1g2) (Rasmussen et al., 2011b) . The C terminus of Gas lies deep in a pocket created by the outward movement of TMVI, and most of the Ga interaction sites are found on TMIII, TMV, TMVI, and ICL2 of the receptor. As shown in Figure 4B , comparison of the agonist-bound G-protein-coupled b 2 AR structure with that of the G-protein-free receptor bound to the inverse agonist carazolol showed significant conformational rearrangements that are similar to those observed for the active opsin. The noticeable differences were a larger outward movement and bending of TMVI and the formation of a bulge in TMV that positions a serine residue (S207) closer to the agonist, providing a structural explanation for the well-known increase in agonist affinity promoted by G protein coupling. Together, these changes represent key determinants of the allosteric transition toward a receptor state activating the G protein.
Nucleotide Exchange
The three structures that incorporate fragments of G proteins or G-protein-mimetics also provide insight into how GPCRs facilitate nucleotide exchange and, hence, initiate signaling cascades. The receptor-coupled structures of the G proteins show that the helical domain of Ga undergoes a major rigidbody rotation of almost 130 upon receptor engagement (Figure 4B ) that was previously predicted by modeling (Cherfils and Chabre, 2003) and biophysical studies (Galé s et al., 2006) . ; bottom left, covalently bound to the agonist procaterol (PDB ID: 3PDS); and top right, bound to the agonist BI-167107 in the presence of Ga s b1g2 (PDB ID: 3SN6). Black dotted lines and circles illustrate the position of TMVI and TMVII in the inverse agonist-bound (inactive state) structure, whereas yellow dotted lines illustrate their position in the Gs and agonist-bound structure (active state). The TM movements from the inactive to active states are indicated by yellow and orange arrows. It should be noted that the large movements of the receptor leading to its open and active conformation were observed only in the presence of both agonist and G protein (top right). The structure obtained in the presence of the agonist alone (bottom left) was similar to the inactive structure obtained in the presence of inverse agonist (top left). To illustrate the conformational rearrangement of the G protein during the activation process, the helical domain structure of the nucleotide (GTPƴS)-bound heterotrimeric Gs (PDB ID: 1AZS) was overlaid on the structure of the receptor-bound Gas (bottom right). The blue dotted arrow indicates the large rigid-body movement of the helical domain of Ga s that suggests a possible structural basis for the nucleotide exchange promoted by receptor activation.
The G-protein-bound nucleotide is pinched between the GTPase and the helical domain in the inactive heterotrimeric G protein structures (Wall et al., 1995) , and this movement provides a possible structural basis for the nucleotide exchange promoted by receptor activation (Rasmussen et al., 2011b; Chung et al., 2011) . These receptor conformational rearrangements underlying G protein activation may be shared by many GPCRs. Ligand-Promoted Activation Besides b 2 AR and b 1 AR, the A 2A AR is the only other GPCR that has been crystallized in the presence of both agonists and antagonists. Focusing on the chemical differences between agonists and antagonists reveals molecular interactions that could explain early events in activation. For the bARs, the extent of binding of the hydroxyl groups of their catecholamine ligands may be essential to promote the reorganization of TMV, TMVI, and TMVII, yielding the active conformation . In the case of the A 2A AR, the ribose group of agonists binds directly to residues in TMVII, leading to a reconfiguration of the NPXXY motif (Lebon et al., 2011; Xu et al., 2011) , which suggests an important role for TMVII in the transition of A 2A AR toward its active state. Yet, the available agonist-bound structures of A 2A AR most likely do not represent the fully activated state of the receptor because the TMVI only undergoes a modest outward movement that is insufficient to allow heterotrimeric G protein engagement. It is tempting to speculate that this movement could be facilitated by the presence of a G protein. This is consistent with the fact that, for the b 2 AR, major structural changes occur only in the presence of the G protein or the Gprotein-mimicking nanobody (Rasmussen et al., 2011b) . Thus, it can be hypothesized that conformational changes leading to receptor activation are driven or at least stabilized in part by G protein coupling and not only by ligand binding.
The agonist-bound structures of bAR and A 2A AR suggest that, although the global molecular rearrangement leading to an active state is very similar among class A GPCRs (Figure 4B ), the specific ligand-receptor contacts triggering the activation can differ. However, it is noteworthy that, in both cases, the receptor domains involved in the binding of the agonists are implicated in the activation transition, suggesting that agonists most likely act by stabilizing at least one of the distinct conformational rearrangements involved in the propagation of the activation transition. In addition, the observation that the A 2A AR can adopt a structure with an activated-like TMVII conformation while having a closed TMVI is a clear illustration of the conformational plasticity of GPCRs and suggests that the various features of an activated state can be differentially controlled. This may help explain how some ligands can selectively activate only a subset of the effectors that can be engaged by a given receptor, which is a concept known as functional selectivity or ligandbiased signaling (Galandrin et al., 2007) .
Receptor Activation circa 2012
The available crystal structures lead to the reassessment of some hypotheses that were formulated a decade ago about the receptor activation process based on the structure of darkadapted rhodopsin. First, the ionic lock between the Arg of the DRY motif and a negatively charged residue on TMVI that was proposed as a major determinant of the inactive receptor state as described above (Figure 2) are not present in all antagonistbound structures. As an example, the ionic lock is not formed in the structure of the b 2 AR cocrystalized with the antagonist carazolol (Figure 2) . In fact, only three receptor structures (A 2A AR, b 1 AR, and D 3 R) show this ionic contact. Even for those three receptors, only a subset of the antagonist-bound structures obtained showed a closed ionic lock (Doré et al., 2011; Moukhametzianov et al., 2011) , suggesting that this polar interaction may oscillate between open and closed in the basal state, thus explaining the constitutive (agonist-independent) activity of the receptor. Alternative stabilization strategies of the inactive state, such as nonionic interactions between the DRY motif and TMVI, are emerging Hanson et al., 2012; Manglik et al., 2012; Thompson et al., 2012; Wu et al., 2010 Wu et al., , 2012 . Additional structures will be required to develop a more definitive view of how inactive receptor conformations are stabilized in the presence or absence of inverse agonists or neutral antagonists.
Another prediction made from the early rhodopsin structures was that the movement of TMVI is triggered by the ligandinduced repacking of a few residues that acts as a ''toggle switch'' in the vicinity of a conserved TMVI proline kink through rotation of their side chains (rotamerization). Yet, with the exception of the muscarinic receptors (Haga et al., 2012; Kruse et al., 2012) , no rotameric transition of these residues was observed, even in the cases of the opsin/transducin, b 2 AR/nanobody, and b 2 AR/heterotrimeric G protein complexes that likely represent fully active structures. Thus, although they could still represent an important structural element supporting receptor activation, their rotamerization may not be required for receptor activation.
Oligomerization in Signaling
A large body of biochemical and biophysical work supports the notion that GPCRs can form physiologically relevant oligomers (Angers et al., 2002) . Although dimers and larger oligomers were detected in some of the early rhodopsin crystals, they were largely attributed to crystallization artifacts. The first b 2 AR structure was also solved as a dimer , but the interactions mainly occurred through associated cholesterol and palmitate molecules with very little involvement of protein-protein contacts, which again raised questions about the physiological relevance of oligomerization. Dimers found within three of the recent structures ( Figure 5 ) have renewed interest in dimerization in GPCR function. The CXCR4 structures revealed a consistent homodimer interface of 850Ǻ 2 of buried surface, including TMV and TMVI (Wu et al., 2010) . The m-opioid receptor (mOR) structure presents two dimer interfaces: a small one involving a TMI-TMII-helix 8 interaction with 615 Å 2 of buried surface and a larger one between TMV and TMVI covering 1492 Å 2 of buried surface . The presence of two distinct interfaces on opposite sides of the receptor offers a plausible structural basis for the formation of higher-order oligomers. Of notice, some of the residues involved in binding the opioid ligands are in direct contact with the amino acids present at the TMV-TMVI dimerization interface, providing a mechanism for the allosteric regulation of the dimerization process. Also, the observation that T279, which stabilizes the closed position of TMVI in the inactive receptor state by interacting with R165 of the DRY motif, is packed within the TMV-TMVI interface offers a possible mechanism for interprotomer regulation of receptor activity ( Figure 5 ). However, the TM5-TM6 interface is not present in the k-opioid receptor (kOR) dimer structure. Indeed, only one interface (1100 Å 2 of buried surface), involving the TMI, TMII, and helix 8, is visible in this structure . The absence of the TMV-TMVI interface in the kOR structure is somewhat surprising given the high level of sequence identity with the mOR in these TMs and may be due to the steric hindrance from the two T4 lysozyme inserts included to aid crystallization of kOR. Whether the dimerization interfaces revealed by the recently solved structures correspond to the functionally relevant dimers will require additional studies involving sitedirected mutagenesis and biochemical and biophysical approaches, but the structures provide rational starting points for this work.
Conclusion
The recent flurry of high-resolution GPCR structures represents a true renaissance for GPCR research. Although much remains to be done to fully understand the precise molecular mechanisms controlling receptor activities, the achievements of the last 5 years provide the foundation of what promises to be very exciting times for structure-based molecular pharmacology and drug discovery. An emerging theme stems from the observation that GPCRs function as molecular hubs that can engage several distinct G proteins, as well as G-protein-independent signaling pathways, and that different ligands promote the engagement of distinct subsets of effectors (Galandrin et al., 2007) . At the molecular level, such ligand-biased signaling is believed to result from the stabilization of different active conformations of the receptors (Bokoch et al., 2010) . A future challenge for structural biology will therefore be to provide high-resolution images of these different receptor states with the goal of designing ligands-and ultimately drugs-to selectively control specific functions. As discussed above, the structures obtained when cocrystalizing receptors with ligands displaying distinct efficacy profiles revealed very similar structures, indicating that solving the structures of receptor-ligand complexes may not be sufficient to fully explore the conformational plasticity of GPCRs underlying their rich biology. The observation that cocrystallization with a G protein or a mimic was needed to reveal a fully active conformation suggests that solving structures of GPCRs in complex with specific effectors such as different G proteins, b-arrestins, or GPCR kinases will be needed to unravel the true diversity of receptor conformations. 
